Development, Drug Delivery Systems and Generic Drugs

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Development

Drug Delivery Systems

Generic Drugs

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

FDA Law Blog

SEPTEMBER 19, 2023

The FTC expressed concern that patent listings that do not meet the statutory criteria undermine the competitive process, may disincentivize investment in developing generic and follow-on products, and reduce patient access to more affordable drugs thereby increasing costs to the healthcare system.

Drugs

Drugs Branding Drug Delivery Systems Generic Drugs

Conducting a Biopharmaceutical Freedom-to-Operate (FTO) Analysis: Key Considerations for Generic Drug Stability Testing

Drug Patent Watch

MARCH 11, 2025

Unlocking the Path to Generic Drug Development: A Freedom to Operate Analysis As a generic drug manufacturer, navigating the complex landscape of biopharmaceutical development can be daunting. But what exactly is an FTO analysis, and why is it essential for your generic drug stability testing?

Generic Drugs

Generic Drugs Drug Delivery Systems Drugs Drug Delivery

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Clinical Research Informer

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

Conducting a Biopharmaceutical Freedom-to-Operate (FTO) Analysis: Key Considerations for Generic Drug Stability Testing

Webinars

Stay Connected